CP Guojian Pharmaceutical
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A subsidiary of Shanghai Pharma developing and manufacturing innovative biologics and biosimilars.
OncologyImmunology
Technology Platform
Integrated biologics platform encompassing R&D, process development, and large-scale GMP manufacturing for antibodies and other proteins.
Opportunities
Leveraging SPH's distribution dominance to efficiently commercialize biosimilars and novel biologics in China's vast hospital network.
Risk Factors
Pricing erosion in the biosimilar market and potential challenges in transitioning from a biosimilar focus to innovative drug development.
Competitive Landscape
Operates in the competitive Chinese biosimilars market, contending with other SPH subsidiaries, Hengrui, and Innovent.